8月21日，1药网(YI)盘中上涨2.43%，截至00:24，报7.17美元/股，成交2.82万美元，总市值6214.55万美 元。 1药网旗下拥有:B2C医药平台"1药网"、互联网医院"1诊",B2B医药平台"1药城",通过创新的S2B2C的模 式,全面实现B端和C端、线上和线下、自营和平台、医+药+保险的融合发展。2018年,1药网成功登陆美 国纳斯达克,股票代码"YI",成为中国互联网医药健康赴美上市第一股。 大事提醒： 本文源自：金融界 9月4日，1药网将披露2025财年中报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际 披露日期以公司公告为准）。 作者：行情君 资料显示，1药网公司是111集团的境外控股公司。1药网由于刚和刘峻岭于2010年创建,是中国互联网医 药健康的领军企业,致力于用数字科技将患者和药品及医疗服务有机连接,打造中国最大的医药健康平 台。 财务数据显示，截至2025年03月31日，1药网收入总额35.29亿人民币，同比增长0.02%；归母净利 润-1764.9万人民币，同比减少28.12%。 1药网基于在互联网科技、智能供应链、全渠道药品商业化、云服务方面建立的优势,与 ...

本次活动中，京东健康联合腾讯广告、快手磁力引擎、微博、巨量引擎、网易云音乐、B站、知乎等多 个渠道共同启动品牌全域增长计划，共同整合了京东健康站内外的资源优势，通过全域数字化营销，为 品牌合作伙伴提供全方位的支持，来满足用户个性化、多样化的医药消费新需求。 8月18日，以"精准营销赋能，通向高效增长"为主题的2025西普会——京东健康特约专场在海南博鳌举 行。与会嘉宾共同探讨在面对市场多重挑战下，如何通过精准营销实现健康产业的高效增长。 北京同仁堂数字科技有限公司总经理孙恺分享了如何通过与京东健康合作开展年轻化营销，实现老字号 的营销变革。今年京东为北京同仁堂京东超级品牌日营销定制解决方案，一站式覆盖超品传播全周期 品、效、销全媒介链路打通，最终实现超过23亿的曝光，活动爆发期28小时内，北京同仁堂产品销售同 比增长超7倍、用户点击同比增长超3倍；重点品类销售成绩亮眼，妇科用药、补益类用药和中风用药均 登顶行业销量TOP1。 孙恺认为，在数字化的时代，京东健康的精细化运营可以更好地帮助品牌精准触达目标用户，结合北京 同仁堂在中医药行业的产品研发优势和专家资源，为消费者提供更专业更值得信赖的品牌和产品服务， 提 ...

8月19日，1药网(YI)盘中上涨2.96%，截至02:41，报6.95美元/股，成交3.28万美元，总市值6023.87万美 元。 财务数据显示，截至2025年03月31日，1药网收入总额35.29亿人民币，同比增长0.02%；归母净利 润-1764.9万人民币，同比减少28.12%。 大事提醒： 9月4日，1药网将披露2025财年中报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际 披露日期以公司公告为准）。 资料显示，1药网公司是111集团的境外控股公司。1药网由于刚和刘峻岭于2010年创建,是中国互联网医 药健康的领军企业,致力于用数字科技将患者和药品及医疗服务有机连接,打造中国最大的医药健康平 台。 1药网基于在互联网科技、智能供应链、全渠道药品商业化、云服务方面建立的优势,与药企、药品流通 商、保险企业等合作伙伴共建供应链服务平台,为B端的药店、医生赋能,从而更好地服务用户(S2B2C)。 1药网通过数字化手段重构医药健康的产业价值链,让需求和供给实现更高效的匹配,为中国大众的就医买 药提供完整的解决方案以及实惠和方便。 1药网旗下拥有:B2C医药平台"1药网"、互联网医院"1诊",B2 ...

Core Viewpoint - 1药网 (YI) is a leading player in China's internet healthcare sector, focusing on connecting patients with pharmaceuticals and medical services through digital technology, aiming to create the largest healthcare platform in China [2]. Financial Performance - As of March 31, 2025, 1药网 reported total revenue of 3.529 billion RMB, reflecting a year-on-year growth of 0.02% [1]. - The company's net profit attributable to shareholders was -17.649 million RMB, a decrease of 28.12% year-on-year [1]. Upcoming Events - 1药网 is scheduled to disclose its mid-year report for the fiscal year 2025 on September 4, 2024, with the actual disclosure date subject to company announcements [2]. Company Overview - 1药网, established in 2010 by Liu Junling, is a subsidiary of 111 Group and has become a leader in the Chinese internet healthcare industry [2]. - The company leverages its strengths in internet technology, smart supply chains, omnichannel commercialization of pharmaceuticals, and cloud services to build a supply chain service platform in collaboration with pharmaceutical companies, distributors, and insurance firms [2]. - 1药网 operates various platforms, including the B2C pharmaceutical platform "1药网," the internet hospital "1诊," and the B2B pharmaceutical platform "1药城," utilizing an innovative S2B2C model to integrate B-end and C-end services [2]. - In 2018, 1药网 successfully listed on NASDAQ under the ticker "YI," becoming the first Chinese internet healthcare company to go public in the U.S. [2].

8月14日，1药网(YI)盘中上涨4.89%，截至22:47，报6.608美元/股，成交5783.0美元，总市值5727.44万 美元。 财务数据显示，截至2025年03月31日，1药网收入总额35.29亿人民币，同比增长0.02%；归母净利 润-1764.9万人民币，同比减少28.12%。 本文源自：金融界 作者：行情君 大事提醒： 9月4日，1药网将披露2025财年中报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际 披露日期以公司公告为准）。 1药网基于在互联网科技、智能供应链、全渠道药品商业化、云服务方面建立的优势,与药企、药品流通 商、保险企业等合作伙伴共建供应链服务平台,为B端的药店、医生赋能,从而更好地服务用户(S2B2C)。 1药网通过数字化手段重构医药健康的产业价值链,让需求和供给实现更高效的匹配,为中国大众的就医买 药提供完整的解决方案以及实惠和方便。 1药网旗下拥有:B2C医药平台"1药网"、互联网医院"1诊",B2B医药平台"1药城",通过创新的S2B2C的模 式,全面实现B端和C端、线上和线下、自营和平台、医+药+保险的融合发展。2018年,1药网成功登陆美 国纳斯达克,股 ...

Group 1: Core Concepts of Collaboration and Innovation - The ultimate pursuit of innovation is not merely a competition at the technical level, but rather achieving sustainable social value through collaborative co-creation [1] - Bayer's three business units demonstrate the practice of "collaborative co-creation" by empowering local innovation, extending value reach, and activating industry dynamics [1][4] - Bayer Co.Lab aims to accelerate local biotech innovation in China by linking global networks and empowering startups through an open ecosystem [3][7] Group 2: Bayer Co.Lab and Its Impact - Bayer Co.Lab has successfully integrated with local innovation, exemplified by the rapid growth of Ruizheng Gene, which achieved significant milestones after joining the platform [3][4] - The platform employs a venture capital-style rigorous selection mechanism to identify and nurture promising innovations that align with Bayer's global strategic focus [3][4] - Bayer Co.Lab has been recognized as an open innovation center, facilitating connections between policy resources and industry ecosystems [7] Group 3: Digital Health Services and Consumer Reach - Bayer's health consumer division leverages digital platforms like Meituan to transform laboratory innovations into accessible health services, creating a comprehensive service ecosystem [8][10] - The collaboration with Meituan has enabled Bayer to overcome traditional retail limitations, enhancing the efficiency of health service delivery [10][11] - Bayer's digital strategy has successfully expanded its customer base, reaching diverse demographics including young users and underserved markets [12] Group 4: Agricultural Initiatives and Local Adaptation - Bayer's "Lingfeng Plan" aims to empower small farmers in China by providing innovative products, technology, and services tailored to local agricultural conditions [13][19] - The plan addresses the unique characteristics of China's agricultural environment, focusing on localized service models to meet farmers' needs [15][19] - Through partnerships with retailers, Bayer has established a network of "Lingfeng Stores" to enhance service delivery and support for farmers [16][19] Group 5: Sustainable Value Creation - Bayer's initiatives reflect a commitment to balancing economic benefits with social value, achieving sustainable value gains through collaborative efforts [19] - The integration of global agricultural innovations with localized service networks is key to addressing the challenges faced by small farmers [19] - The overarching theme of collaborative co-creation enhances the ecological dynamics of Bayer's strategic layout and practical value delivery [19]

Core Viewpoint - 1药网 (YI) has experienced a stock price increase of 5.02%, with a current share price of $7.278 and a total market capitalization of $63.08 million. Financial data indicates a total revenue of 14.401 billion RMB for the year ending December 31, 2024, representing a year-on-year decrease of 3.66%, while the net profit attributable to shareholders is -64.743 million RMB, showing a significant year-on-year increase of 83.51% [1][2]. Group 1 - 1药网 is a leading player in China's internet healthcare sector, founded in 2010 by Liu Junling, and aims to connect patients with pharmaceuticals and medical services through digital technology [2]. - The company operates a supply chain service platform in collaboration with pharmaceutical companies, distributors, and insurance firms, empowering B-end pharmacies and doctors to better serve users through an S2B2C model [2]. - 1药网 has restructured the pharmaceutical health industry's value chain using digital means, providing efficient matching of supply and demand, and offering comprehensive solutions for the public's medical and pharmaceutical needs [2]. Group 2 - The company owns several platforms, including the B2C pharmaceutical platform "1药网," the internet hospital "1诊," and the B2B pharmaceutical platform "1药城," achieving integration across B-end and C-end, online and offline, and self-operated and platform models [2]. - 1药网 successfully went public on NASDAQ in 2018 under the ticker "YI," becoming the first Chinese internet healthcare company to list in the United States [2].

Core Viewpoint - 1药网 (YI) has experienced a slight increase in stock price, while its financial performance shows a decline in revenue but a significant increase in net profit [1][2]. Financial Performance - As of December 31, 2024, 1药网 reported total revenue of 14.401 billion RMB, a year-on-year decrease of 3.66% [1]. - The net profit attributable to the parent company was -64.743 million RMB, reflecting a year-on-year increase of 83.51% [1]. Company Overview - 1药网 is a leading player in China's internet healthcare sector, founded in 2010 by Liu Junling, and is a subsidiary of 111 Group [2]. - The company aims to connect patients with pharmaceuticals and medical services through digital technology, establishing itself as the largest healthcare platform in China [2]. - 1药网 operates various platforms, including the B2C pharmaceutical platform "1药网," the internet hospital "1诊," and the B2B pharmaceutical platform "1药城," utilizing an innovative S2B2C model [2]. - The company went public on NASDAQ in 2018, becoming the first Chinese internet healthcare company to list in the U.S. [2].

Core Viewpoint - 1药网 (YI) is experiencing a decline in revenue while showing significant growth in net profit, indicating a potential shift in its financial dynamics [1][2]. Financial Performance - As of December 31, 2024, 1药网 reported total revenue of 14.401 billion RMB, a year-on-year decrease of 3.66% [1]. - The net profit attributable to the parent company was -64.743 million RMB, reflecting a year-on-year increase of 83.51% [1]. Company Overview - 1药网 is a leading player in China's internet healthcare sector, founded in 2010 by Liu Junling, and is a subsidiary of 111 Group [2]. - The company aims to connect patients with pharmaceuticals and medical services through digital technology, striving to create the largest healthcare platform in China [2]. - 1药网 has established a supply chain service platform in collaboration with pharmaceutical companies, distributors, and insurance firms, enhancing service delivery to B-end clients such as pharmacies and doctors [2]. Business Model - The company employs a digital approach to reconstruct the pharmaceutical health industry value chain, facilitating efficient matching of supply and demand [2]. - 1药网 operates several platforms, including the B2C pharmaceutical platform "1药网," the internet hospital "1诊," and the B2B pharmaceutical platform "1药城," utilizing an innovative S2B2C model [2]. - The integration of B-end and C-end services, online and offline operations, and the convergence of medicine, pharmaceuticals, and insurance is a key focus for the company [2]. Market Position - 1药网 successfully listed on NASDAQ in 2018 under the ticker symbol "YI," marking it as the first Chinese internet healthcare company to go public in the U.S. [2].

Core Viewpoint - 1药网 (YI) is experiencing a decline in revenue while showing significant growth in net profit, indicating a potential shift in its financial dynamics [1][2]. Financial Performance - As of December 31, 2024, 1药网 reported total revenue of 14.401 billion RMB, a year-on-year decrease of 3.66% [1]. - The net profit attributable to the parent company was -64.743 million RMB, reflecting a year-on-year increase of 83.51% [1]. Company Overview - 1药网 is a leading player in China's internet healthcare sector, founded in 2010 by Liu Junling, and is a subsidiary of 111 Group [2]. - The company aims to connect patients with pharmaceuticals and medical services through digital technology, striving to create the largest healthcare platform in China [2]. - 1药网 operates various platforms, including the B2C pharmaceutical platform "1药网," the internet hospital "1诊," and the B2B pharmaceutical platform "1药城," utilizing an innovative S2B2C model [2]. - The company went public on NASDAQ in 2018 under the ticker "YI," marking it as the first Chinese internet healthcare company to list in the U.S. [2].